Publication Name	World Journal of Gastroenterology
Manuscript ID	4514
Country	Italy

Received	2013-07-03 09:25
Peer-Review Started	2013-07-03 20:01
To Make the First Decision	2013-07-26 18:40
Return for Revision	2013-08-06 10:41
Revised	2013-09-02 23:13
Second Decision	2013-09-16 17:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-09-17 06:30
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-08 19:11
Publish the Manuscript Online	2013-11-18 10:59

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Rifaximin and Crohn's disease
Manuscript Source	Invited Manuscript
All Author List	Cosimo Prantera and Maria Lia Scribano
Funding Agency and Grant Number
Corresponding Author	Cosimo Prantera, MD, Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo-Forlanini, Circonvallazione Gianicolense 87, 00152 Rome, Italy. prantera@tin.it
Key Words	Crohn's disease; Intestinal microbiota; Non-absorbable antibiotic; Rifaximin
Core Tip	In this letter to the Editor we report some considerations concerning the article entitled "Microbial manipulation as primary therapy for Crohn's disease" written by Longman and Swaminath. In the article the authors analyzed our paper on the use of rifaximin as primary therapy in active Crohn's disease. The post-hoc analysis of our study showed that early-stage disease, colonic involvement and a C reactive protein level > 5 mg/L were associated with a significant higher efficacy of rifaximin. We also discuss the role of rifaximin against intestinal bacteria and the clinical situations to explore further in controlled studies with antibiotics.
Publish Date	2013-11-18 10:59
Citation	Prantera C, Scribano ML. Rifaximin and Crohn’s disease. World J Gastroenterol 2013; 19(42): 7487-7488
URL	http://www.wjgnet.com/1007-9327/full/v19/i42/7487.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i42.7487

Full Article (PDF)	WJG-19-7487.pdf
Manuscript File	4514-Review.doc
Answering Reviewers	4514-Answering reviewers.pdf
Copyright License Agreement	4514-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4514-Language certificate.pdf
Peer-review Report	4514-Peer reviewer(s).pdf
Scientific Editor Work List	4514-Scientific editor work list.doc